RxDoctor Payments Data

Rita Pichardo Geisinger, MD

Dermatopathology · Winston Salem, NCNPI 1255316311

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,775 of the $30,401 with a category attached, or 81.5%. 8 manufacturers reported payments, led by Novartis at 48.2% of the total. Reporting peaked in 2024 at $11,581 and has fallen 82.5% since, to $2,024 in 2025.

$30,401in general payments, 2019–2025

Across 49 payments — averaging $620.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$15K
  • UCB, Inc.$11K
  • AbbVie$4K
  • Galderma Laboratories, L.p.$361
  • Aroa Biosurgery Incorporated$70
  • Johnson & Johnson$57
  • plus $54 from 2 others
$2,363,728in research payments, 2019–2025

Across 62 payments — averaging $38,125 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2M
  • UCB SA$211K
  • Incyte Corporation$87K
  • Sanofi US Services Inc.$22K
  • Novartis$1K

What the payments were for

  • Consulting fees$24,77581%
  • Travel & lodging$3,36111%
  • Food & beverage$2,2657%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$56,588
Medicare patients
454
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab89$1,154,790
Cosentyx Unoready PenSecukinumab59$600,424
InflectraInfliximab-Dyyb19$313,407
RemicadeInfliximab27$281,156
Dupixent PenDupilumab74$273,598
Skyrizi PenRisankizumab-Rzaa11$225,560
AvsolaInfliximab-Axxq27$133,760
Dupixent SyringeDupilumab12$43,538
Acitretin11$5,384
Clobetasol Propionate157$4,791
Triamcinolone Acetonide248$3,444
Fluocinonide65$2,757
Finasteride283$2,599
Dapsone44$2,557
Minoxidil237$2,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRemicade$57$281,15627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other dermatopathology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →